Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients-Reference-Cited by-同舟云学术

Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients

Published:2016-05 Issue: Volume:129 Page:52-57
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Giacomelli Andrea,Oreni Letizia,Franzetti Marco,Di Cristo Valentina,Colella Elisa,Ridolfo Anna Lisa,Galli Massimo,Rusconi Stefano^ORCID

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference20 articles.

1. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors;Anderson;J. Antimicrob. Chemother.,2009

2. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction;Baril;HIV Med.,2014

3. Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients;Bonora;Curr. HIV Res.,2014

4. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (The REYAGEN study);Bonora;J. Antimicrob. Chemother.,2015

5. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials;Carey;J. AntimicrobChemother,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis;PLOS ONE;2019-07-29

Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects

;Drug Design, Development and Therapy;2019-07